Trial reportBMC pregnancy and childbirth2026
Study protocol FRENCH-ARRIVE: labor induction in low-risk nulliparous women at 39 weeks of gestation to reduce cesarean births: a randomized trial of induction versus expectant management in France.
Trial report in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04799912 (Labor Induction in Low-risk Nulliparous Women at 39 Weeks of Gestation to Reduce Cesarean), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Labor Induction in Low-risk Nulliparous Women at 39 Weeks of Gestation to Reduce Cesarean: A Randomized Trial of Induction Versus Expectant Management in France (FRENCH-ARRIVE)
Who cites it
1 citing paper in PubMed.
- Optimal timing for induction of labor in normotensive women: A retrospective cohort study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe ARRIVE trial showed that elective induction of labor at 39 weeks for low-risk nulliparous women compared to expectant management reduced cesarean delivery rates with a nonsignificant trend toward decreased perinatal morbidity. However, the generalizability of these findings to other health care systems and obstetric contexts outside of the United States remains uncertain.
methodsThe FRENCH-ARRIVE multicenter, randomized controlled trial with two parallel groups, modeled on the ARRIVE trial, will include 4200 low-risk nulliparous women with singleton pregnancies from 37 weeks 0 days through 38 weeks 6 days of gestation. Women will be randomized in a 1:1 ratio to either elective induction between 39 weeks 0 days and 39 weeks 4 days of gestation or expectant management. The primary outcome will be the incidence of cesarean deliveries after randomization, regardless of indication. This study will have a power of 80% to show a 20% reduction in the cesarean incidence from 15.0% to 12.0%. Secondary outcomes will include indicators of maternal and perinatal morbidity and of health-care resource utilization, defined consistently with those of the ARRIVE trial to allow meaningful comparisons. DISCUSSION: This large, multicenter, randomized controlled trial, as the first replication of the ARRIVE trial in a different setting, aims to compare the effect of elective induction of labor at 39 weeks of gestation versus expectant management on the incidence of cesarean delivery in low-risk nulliparous women.
trial registrationClinicalTrials.gov NCT04799912 (March 12, 2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.